人参次苷H滴丸对慢性温和不可预见性应激大鼠的抗抑郁作用

目的探讨人参次苷H滴丸对慢性温和不可预见性应激结合孤养方法建立抑郁模型大鼠的抗抑郁作用及其作用机制。方法 96只大鼠随机分为对照组、模型组、氟西汀组和人参次苷H滴丸28、56、112 mg/kg组,每组16只。除对照组外各组分别孤养并接受5周慢性温和不可预见性应激刺激造模。同时氟西汀(10 mg/kg)组、人参次苷H滴丸28、56、112mg/kg组ig给药,对照组、模型组ig相应体积(10 mL/kg)纯水。对大鼠体质量变化、糖水消耗比、敞箱实验行为学评分进行比较,对血浆皮质酮(CORT)、皮层、海马区神经营养因子(BDNF)、5-羟色胺(5-HT)、多巴胺(DA)、去甲肾上腺素(NE)水平变化进行检测。尼氏染色后观察海马CA1、CA3区神经元数目和形态。结果与模型组比较,人参次苷H滴丸56、112 mg/kg组体质量显著升高(P0.05),人参次苷H滴丸28、56、112 mg/kg组糖水消耗比显著升高(P0.01);敞箱实验中人参次苷H滴丸56 mg/kg组大鼠水平运动得分显著提高(P0.05),56、112 mg/kg组垂直运动得分显著提高(P0.05、0.01);人参次苷H滴丸28、56、112 mg/kg组大鼠血浆CORT水平均有所降低,但差异并无统计学意义;人参次苷H滴丸56 mg/kg组皮层、海马BDNF水平显著升高(P0.05),人参次苷H滴丸56、112 mg/kg组大鼠皮层、海马5-HT水平显著升高(P0.05、0.01);人参次苷H滴丸28、56 mg/kg组大鼠皮层、海马DA水平显著升高(P0.05、0.01);人参次苷H滴丸28、56、112 mg/kg组大鼠皮层、海马NE水平升高十分显著(P0.01)。人参次苷H滴丸28、56、112 mg/kg组海马CA1、CA3区锥体细胞形态较为规则,排列较为松散,锥体细胞数量相对增多。结论人参次苷H滴丸具有抗抑郁作用,其作用机制可能是通过改善抑郁大鼠肾上腺轴功能亢进症状,提高模型大鼠皮层与海马5-HT、DA、NE水平,上调BDNF表达,以及抑制海马CA1、CA3区神经元锥体细胞的凋亡。

Antidepressant effect of Secondary Ginsenoside H Driping Pills on chronic unpredictable mild stress rats

Objective To investigate the antidepressant effect of Secondary Ginsenoside H Driping Pills on chronic unpredictable mild stress rats, and explore its mechanisms. Methods SD rats (96) were divided into control group, model group, fluoxetine group, and Secondary Ginsenoside H Driping Pills (28, 56, and 112 mg/kg) groups, and each group had 16 rats. Rats in each group were given social isolation and chronic unpredictable mild stress (CUMS) for 5 weeks to establish models except the control group. At the same time, rats in the fluoxetine (10 mg/kg) group and Secondary Ginsenoside H Driping Pills (28, 56, and 112 mg/kg) groups were ig administered with drugs, while rats in the control group and model group were ig corresponding volume (10 mL/kg) pure water. The body weights, sucrose consumption ratio, and open field test scores were compared. The plasma corticosterone (CORT), brain derived neurotrophic factor (BDNF), serotonin (5-HT), dobaamine (DA), norepinephrine (NE) levels in the hippocampus and frontal cortex were detected. After Nissl staining, the number and morphology of neurons in CA1 and CA3 regions of hippocampus were observed. Results Compared with the model group, body weights in Secondary Ginsenoside H Driping Pills (56 and 112 mg/kg) groups were significantly increased (P < 0.05), and sucrose consumption ratios in Secondary Ginsenoside H Driping Pills (28, 56, and 112 mg/kg) groups were significantly decreased (P < 0.01). Horizontal movement scores in Secondary Ginsenoside H Driping Pills (56 mg/kg) group improved significantly (P < 0.05), and vertical motion scores in Secondary Ginsenoside H Driping Pills (56 and 112 mg/kg) groups also improved significantly (P < 0.05, 0.01). The plasma levels of CORT in Secondary Ginsenoside H Driping Pills (28, 56, and 112 mg/kg) groups were decreased, but the difference was not statistically significant. Cortex and hippocampus BDNF levels in Secondary Ginsenoside H Driping Pills (56 mg/kg) group were increased significantly (P < 0.05); cortex and hippocampus 5-HT levels in Secondary Ginsenoside H Driping Pills (56 and 112 mg/kg) groups were increased significantly (P < 0.05, 0.01); cortex and hippocampus DA levels in Secondary Ginsenoside H Driping Pills (28 and 56 mg/kg) groups were significantly increased (P < 0.05, 0.01); and cortex and hippocampus NE levels in Secondary Ginsenoside H Driping Pills (28, 56, and 112 mg/kg) groups were increased significantly (P < 0.01). The pyramidal cells in CA1 and CA3 regions of the hippocampus in Secondary Ginsenoside H Driping Pills (28, 56, and 112 mg/kg) groups were more regular, loosely arranged, and the number of pyramidal cells increased relatively. Conclusion Secondary Ginsenoside H Driping Pills have antidepressant effect, and the mechanism may be related to improve the symptoms of adrenal axis hyperfunction, improve cerebral cortex and hippocampus 5-HT, DA, and NE levels, up-regulate the expression of BDNF, and inhibit apoptosis of pyramidal neurons in CA1 and CA3 regions of hippocampus.